Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBITDA (2020 - 2023)

Historic EBITDA for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to -$10.3 million.

  • Candel Therapeutics' EBITDA fell 2736.7% to -$10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$38.4 million, marking a year-over-year decrease of 1057.0%. This contributed to the annual value of -$33.4 million for FY2024, which is 1307.6% up from last year.
  • Latest data reveals that Candel Therapeutics reported EBITDA of -$10.3 million as of Q4 2023, which was down 2736.7% from -$8.9 million recorded in Q3 2023.
  • Candel Therapeutics' 5-year EBITDA high stood at $1.6 million for Q4 2021, and its period low was -$17.1 million during Q2 2021.
  • Its 4-year average for EBITDA is -$8.3 million, with a median of -$8.9 million in 2022.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 11515.96% in 2021, then plummeted by 60758.15% in 2022.
  • Quarter analysis of 4 years shows Candel Therapeutics' EBITDA stood at -$10.5 million in 2020, then skyrocketed by 115.16% to $1.6 million in 2021, then crashed by 607.58% to -$8.1 million in 2022, then decreased by 27.37% to -$10.3 million in 2023.
  • Its last three reported values are -$10.3 million in Q4 2023, -$8.9 million for Q3 2023, and -$9.6 million during Q2 2023.